HOME >> MEDICINE >> NEWS
Possible treatment found for 'chemobrain'

Patients who take medication for cancer often find themselves with a new problem when their treatment ends.

It's called "chemobrain," a common consequence of chemotherapy that causes memory problems, confusion and difficulty in concentrating.

Symptoms of chemobrain can also include lack of focus, inability to organize daily activities, mental confusion, memory loss and decreased mental clarity.

It's estimated that chemobrain occurs in as many as 99 percent of breast and ovarian cancer patients receiving chemotherapy or radiation treatments. Sixty-one percent of these patients continue to experience fatigue and memory problems long after their cancer treatment has stopped.

Now, researchers led by the University of Cincinnati's (UC) Elyse Lower, MD, report a possible new treatment for the problem using the drug dexmethyphenidate (d-MPH).

Dr. Lower, professor of hematology/oncology at UC College of Medicine, recently described the encouraging results of a 14-month, multi-center, Phase 2 study of d-MPH to the annual meeting of the American Society of Clinical Oncology.

The 154 cancer survivors at 21 medical centers showed significant reduction in fatigue and improvement in memory when treated with dosages of 10 mg to 50 mg of d-MPH per day, Dr. Lower said, when compared with a control group receiving a placebo.

All the patients, who had a median age of 53 years, had completed at least four cycles of chemotherapy at least two months before the study began. Ninety percent of them were female (76 percent with breast cancer and 14 percent with ovarian cancer), 79 percent were white and 9 percent were African-American.

"The study showed that up to 50 mg a day of d-MPH is safe and effective for relieving chemobrain in adult cancer patients," said Dr. Lower, "and it should be considered as a treatment."

One of the study participants, Marilyn Metz, had undergone radiation and chemotherapy in 2001 to t
'"/>

Contact: Sheryl Hilton
sheryl.hilton@uc.edu
513-558-4561
University of Cincinnati
7-Jun-2005


Page: 1 2

Related medicine news :

1. Possible new breast cancer gene
2. Possible predictors of relationship violence
3. Possible exposure to nerve agents and brain cancer deaths in Gulf War veterans
4. Spot on treatment for acne
5. New treatment boosts muscle function in myasthenia gravis
6. New treatment effective in counteracting cocaine-induced symptoms
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Preventive treatments in elderly people needs rethinking
9. Osteoporosis screening and treatment may be cost-effective for selected older men
10. Quality of treatment guidelines
11. Green tea holds promise as new treatment for inflammatory skin diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... ... 2017 , ... After a summer-long contest to crown the ... Drivers proudly announced the winners of the HEROtini Mocktail Challenge at the Stockton ... the challenge of competing in three categories: Best HEROtini Mocktail, Top HEROtini Bartender, ...
(Date:9/26/2017)... ... , ... Data Integrity: , The Key to FDA and GMP Compliance, ** ... http://www.fdanews.com/fdadataintegrity , Consider this situation. The FDA gives simple ... be trustworthy and reliable … a more detailed evaluation may be warranted.” , ...
(Date:9/26/2017)... ... 26, 2017 , ... Dr. Kovatis, is a Hospital for ... and Foot Section of the Department of Orthopedic Surgery at Hackensack University Medical ... UMC performing total ankle replacements. Because of this, Dr. Kovatis is often referred ...
(Date:9/26/2017)... , ... September 26, 2017 , ... The 2017 American ... called “The Magic of Fat,” revealed not only the latest about cosmetic procedures to ... be an evolution in cosmetic medicine. , “Fat really is magical, especially when it ...
(Date:9/26/2017)... ... 26, 2017 , ... The Organizing Committee is pleased to ... Pittcon 2018. As of July 1, Adrian C. Michael, Ph.D. (University of Pittsburgh, ... Charles Gardner, (ChemImage Corporation) and selected chairs. , Other members of ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/7/2017)...  Eli Lilly and Company (NYSE: ... to more efficiently focus resources on developing new ... workforce reductions, including those from a U.S. voluntary ... 3,500 positions. With the streamlining ... approximately $500 million that will begin to be ...
Breaking Medicine Technology:
Cached News: